ArticleDermatology and therapy2022

High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers.

Georgios Kokolakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.